Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Isocitrate Dehydrogenase 3 (NAD+) alpha (IDH3A) (Middle Region) Peptid

IDH3A Wirt: Synthetic BP, WB
Produktnummer ABIN8103510
168,15 €
Zzgl. Versandkosten 20,00 € und MwSt
100 μg
Lieferung nach: Deutschland
Lieferung in 6 bis 9 Werktagen

Kurzübersicht für Isocitrate Dehydrogenase 3 (NAD+) alpha (IDH3A) (Middle Region) Peptid (ABIN8103510)

Target

IDH3A (Isocitrate Dehydrogenase 3 (NAD+) alpha (IDH3A))

Quelle

  • 9
Synthetic

Applikation

Blocking Peptide (BP), Western Blotting (WB)
  • Protein Region

    Middle Region

    Verwendungszweck

    IDH3A Peptide - middle region
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Kommentare

    This is a synthetic peptide designed for use in combination with anti-IDH3A antibody ( ARP42238_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Buffer

    Lyophilized powder

    Lagerung

    -20 °C

    Informationen zur Lagerung

    For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
  • Target

    IDH3A (Isocitrate Dehydrogenase 3 (NAD+) alpha (IDH3A))

    Hintergrund

    Targeted Subunit: alpha, mitochondrial

    Background Information: Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases

    Molekulargewicht

    37kDa

    Gen-ID

    3419

    NCBI Accession

    NP_005521

    UniProt

    P50213
Sie sind hier:
Chat with us!